News | Embolic Protection Devices | April 11, 2017

PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device

Pennsylvania hospital system is one of 27 worldwide testing device meant to reduce stroke risk during TAVR

PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device

April 11, 2017 — Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device designed to reduce risk of stroke during transcatheter aortic valve replacement (TAVR).

Aortic stenosis is one of the most common and most serious heart valve diseases. Left untreated, aortic stenosis gradually diminishes quality of life and leads to heart failure and death. The gold standard for treating aortic stenosis has been surgical aortic valve replacement; however, changes in cardiovascular medicine have led to the minimally invasive, catheter-based TAVR procedure for patients deemed too high risk for surgery. Patients having either type of aortic valve replacement are at risk of brain injury that may range from memory loss and speech challenges to debilitating strokes.

The international clinical trial, called REFLECT, studies the safety and efficacy of the Keystone Heart TriGuard cerebral embolic protection device to minimize the risk of cerebral damage during TAVR and other cardiovascular procedures. TriGuard is designed to reduce the amount of embolic debris from traveling through the blood stream to the brain for patients undergoing TAVR. If this debris travels through the blood stream to the brain, it could possibly cause damage that may lead to a stroke or neurocognitive dysfunction, such as memory loss and speech challenges.

"As physicians, we see firsthand the debilitating effects of brain injury following TAVR can have on our patients," stated Mubashir Mumtaz, M.D., FACS, FACC, chief of cardiothoracic surgery, surgical director of structural heart and principal investigator for the trial at PinnacleHealth. "PinnacleHealth CardioVascular Institute is honored to be selected for this elite global trial, studying a major patient safety initiative."

"This device presents the opportunity to minimize brain injury following TAVR and supports our goal to preserve quality of life," stated Hemal Gada, M.D., MBA, interventional cardiologist and medical director of structural heart at PinnacleHealth.

The TriGuard device is shaped to accommodate anatomic variations of the aortic arch in order to provide full coverage to all brain territories.  It is placed via one of the femoral artery access ports typically used in TAVR, thereby eliminating the need for a third puncture site. 

PinnacleHealth is one of 27 hospital systems in the world, and the only hospital in Pennsylvania, enrolling patients in this trial.

Read the article from TCT 2016 “Delirium Significantly Associated With Brain Lesions in Patients Post-TAVR.”

For more information: www.keystoneheart.com

Related Content

Gallery | Cath Lab | October 31, 2019
This is a photo essay of the interventional cardiology and structural heart technologies on the expo floor and discus
The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

Technology | Cath Lab | October 28, 2019
Office based labs (OBLs) and ambulatory surgery centers (ASCs) require a fresh perspective from imaging vendors.
Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

News | Cath Lab | October 28, 2019
October 28, 2019 — Leaders within University Hospitals and the Harrington Heart and Vascular Institute had a vision t
OmniVision Announces Guinness World Record for Smallest Image Sensor

OmniVision's OVM6948 CameraCubeChip, a fully packaged, wafer-level camera module measuring 0.65mm x 0.65mm x 1.158mm, built on OmniVision's OV6948, winner of the Guinness World Record for “The Smallest Image Sensor Commercially Available.”

News | Cath Lab | October 22, 2019
October 22, 2019 — OmniVision Technologies Inc.
People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized...
Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
Overlay Init